Identifying biomarkers that simultaneously reflect inflammation and coagulation status is crucial for early prediction and prevention of VTE in high-risk populations.
Investigators employed the Accelerating Medicines Partnership to identify noninvasive biomarkers of lupus nephritis pathology and treatment response.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback